A detailed history of Blair William & CO transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Blair William & CO holds 5,568 shares of KRYS stock, worth $991,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,568
Previous 5,566 0.04%
Holding current value
$991,660
Previous $1.02 Million 0.98%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$174.7 - $213.66 $349 - $427
2 Added 0.04%
5,568 $1.01 Million
Q2 2024

Aug 12, 2024

SELL
$153.12 - $183.64 $5,512 - $6,611
-36 Reduced 0.64%
5,566 $1.02 Million
Q1 2024

May 09, 2024

SELL
$108.01 - $179.35 $59,405 - $98,642
-550 Reduced 8.94%
5,602 $996,000
Q4 2023

Feb 12, 2024

BUY
$96.0 - $128.29 $1,920 - $2,565
20 Added 0.33%
6,152 $763,000
Q3 2023

Nov 09, 2023

SELL
$108.51 - $130.22 $96,031 - $115,244
-885 Reduced 12.61%
6,132 $711,000
Q2 2023

Aug 11, 2023

SELL
$78.48 - $130.32 $3,139 - $5,212
-40 Reduced 0.57%
7,017 $823,000
Q1 2023

May 12, 2023

BUY
$72.39 - $84.27 $7,239 - $8,427
100 Added 1.44%
7,057 $564,000
Q4 2022

Feb 10, 2023

BUY
$63.14 - $79.9 $36,621 - $46,342
580 Added 9.1%
6,957 $551,000
Q3 2022

Nov 09, 2022

BUY
$64.85 - $82.4 $83,332 - $105,884
1,285 Added 25.24%
6,377 $444,000
Q2 2022

Aug 10, 2022

BUY
$48.93 - $73.47 $249,151 - $374,109
5,092 New
5,092 $334,000
Q1 2022

May 13, 2022

SELL
$51.99 - $72.11 $462,503 - $641,490
-8,896 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$39.81 - $88.24 $3.35 Million - $7.43 Million
-84,242 Reduced 90.45%
8,896 $622,000
Q3 2021

Nov 12, 2021

BUY
$52.01 - $71.77 $1.79 Million - $2.47 Million
34,383 Added 58.52%
93,138 $4.86 Million
Q2 2021

Aug 12, 2021

BUY
$62.14 - $81.82 $285,160 - $375,471
4,589 Added 8.47%
58,755 $4 Million
Q1 2021

May 13, 2021

BUY
$59.42 - $85.46 $1.12 Million - $1.62 Million
18,908 Added 53.63%
54,166 $4.17 Million
Q4 2020

Feb 09, 2021

SELL
$40.64 - $61.38 $30,927 - $46,710
-761 Reduced 2.11%
35,258 $2.12 Million
Q3 2020

Nov 06, 2020

SELL
$37.76 - $48.49 $524,108 - $673,041
-13,880 Reduced 27.82%
36,019 $1.55 Million
Q2 2020

Aug 12, 2020

SELL
$37.03 - $60.0 $406,663 - $658,920
-10,982 Reduced 18.04%
49,899 $2.07 Million
Q1 2020

May 11, 2020

SELL
$35.02 - $65.64 $100,612 - $188,583
-2,873 Reduced 4.51%
60,881 $2.63 Million
Q4 2019

Feb 13, 2020

BUY
$33.17 - $65.23 $174,573 - $343,305
5,263 Added 9.0%
63,754 $3.53 Million
Q3 2019

Nov 12, 2019

BUY
$34.72 - $51.3 $1.36 Million - $2.01 Million
39,225 Added 203.6%
58,491 $2.03 Million
Q2 2019

Aug 13, 2019

SELL
$27.2 - $41.2 $1.28 Million - $1.93 Million
-46,940 Reduced 70.9%
19,266 $776,000
Q1 2019

May 14, 2019

BUY
$19.86 - $32.9 $882,300 - $1.46 Million
44,426 Added 203.98%
66,206 $2.18 Million
Q4 2018

Feb 14, 2019

BUY
$15.03 - $25.38 $327,353 - $552,776
21,780 New
21,780 $453,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.57B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.